Biotech | December 08, 2021
SPARC partners with Visiox for ophthalmic drugs
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
Healtherbs helps in restoring the desired energy levels for daily activity and immunity
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
The product will be commercialized from Unichem's Ghaziabad plant
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
Sciflix is a special Initiative by Lupin to assist future pulmonologists in staying abreast of the latest medical advances relevant to their speciality
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
For the six months ended September 30, 2021, Lyka had reported revenues of Rs 109.87 crore
Subscribe To Our Newsletter & Stay Updated
